IP Library Granted Patent US 8,389,693
Granted Patent B2
US 8,389,693 · App. 13/245,420 · Granted Mar 5, 2013

Stable and soluble antibodies inhibiting TNFα

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,389,693
App. No.
13/245,420
Granted
Mar 5, 2013
Kind
B2
Abstract

The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNFα, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNFα, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNFα-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.

Claims (7)

1. A stable and soluble antibody which specifically binds TNFα, said antibody comprising the sequence of SEQ ID NO: 40, wherein the sequence of SEQ ID NO: 10 in the sequence of SEQ ID NO: 40 is a linker sequence.

2. A stable and soluble antibody which specifically binds TNFα, said antibody comprising a light chain variable domain (VL) comprising the sequence of SEQ ID NO: 1 and a heavy chain variable domain (VH) comprising the sequence of SEQ ID NO: 2 and a linker derived from the sequence of SEQ ID NO: 10.

3. The antibody of claim 1 or 2 , which is an scFv antibody.

4. A pharmaceutical composition comprising the antibody of claim 1 or 2 as a pharmaceutical.

5. The pharmaceutical composition of claim 4 for the production of a medicament for the treatment of or as an in vitro diagnostic for detection of TNFα-associated diseases.

6. A diagnostic or therapeutic composition comprising the antibody of claim 1 or 2 in combination with a pharmaceutically acceptable carrier, diluent or excipient.

7. The antibody of claim 2 , wherein at least one G in the sequence of SEQ ID NO: 10 is changed to a more polar or charged amino acid.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2022
From: CELL MEDICA INC.
To: CELL MEDICA, INC.
Reel/Frame 060529/0195 →
SECURITY INTEREST Recorded Jul 7, 2021
From: CELL MEDICA, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 056782/0954 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2021
From: CELL MEDICA SWITZERLAND AG
To: CELL MEDICA INC.
Reel/Frame 054988/0114 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 23, 2018
From: ESBATECH, A NOVARTIS COMPANY LLC
To: CELL MEDICA SWITZERLAND AG
Reel/Frame 046677/0476 →